(357 days)
Not Found
No
The description focuses on electrochemical measurement of glucose and does not mention any AI/ML components or functionalities.
No
This device is a diagnostic tool used for monitoring blood glucose levels, not for treating a condition. It aids in a diabetes control program by providing measurements, but it does not provide therapy or treatment itself.
Yes
Explanation: The device is used for the quantitative measurement of glucose in capillary whole blood, which is a diagnostic measurement used to monitor blood glucose levels in people with diabetes. Although it explicitly states "not for the diagnosis of or screening for diabetes", monitoring the effectiveness of a diabetes control program is a diagnostic function.
No
The device description explicitly lists hardware components such as a "measuring meter," "test strips," "control solutions," "Lancing Device," and "Lancets," indicating it is a physical system, not software-only.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative measurement of glucose in capillary whole blood from the fingertip and the alternate sites". This involves testing a biological sample (blood) outside the body.
- Device Description: The description details components like a meter, test strips, and control solutions, which are typical for in vitro diagnostic devices used for chemical analysis of biological samples.
- Function: The system measures glucose by analyzing a small electrical current generated in the test strips when blood is applied. This is a chemical reaction occurring in vitro (in the test strip).
- Self-Testing: The system is intended for "self testing outside the body by people with diabetes at home". This reinforces the in vitro nature of the testing.
The definition of an IVD generally includes devices intended for use in the examination of specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This blood glucose monitoring system clearly fits this definition for monitoring purposes.
N/A
Intended Use / Indications for Use
The ACURA PLUS Blood Glucose Meter is intended for use with the ACURA PLUS Blood Glucose Test Strips for the quantitative measurement of glucose in capillary whole blood from the fingertip and the alternate sites such as forearm, palm, thigh and calf. The alternate site testing should be used only during steady-state blood glucose conditions. The ACURA PLUS Control Solutions are for use with the ACURA PLUS Meter and ACURA PLUS Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
The ACURA PLUS Blood Glucose Monitoring System is intended for self testing outside the body by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program. The system is intended to be used by a single person and should not be shared. It is not intended for use on neonates and is not for the diagnosis of or screening for diabetes.
Product codes (comma separated list FDA assigned to the subject device)
CGA, NBW, JJX
Device Description
The ACURA PLUS Blood Glucose Monitoring System (BGMS) measures the glucose in whole blood sample by a small electrical current generated in the test strips and sent to the meter for measurement. The system consists of the following devices: ACURA PLUS Meter (Model GM505RA), ACURA PLUS Test Strips, ACURA PLUS Control Solutions for three different glucose concentration ranges (called "Low", "Normal" and "High" ranges, sold separately), Lancing Device, Lancets, User manual, Quick reference guide and Logbook.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
fingertip and the alternate sites such as forearm, palm, thigh and calf.
Indicated Patient Age Range
Not intended for use on neonates.
Intended User / Care Setting
self testing outside the body by people with diabetes at home
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
To verify whether the modified feature operates correctly, the validation study was conducted. The test results confirmed that the modified features operated properly. Thus, ACURA PLUS BGMS demonstrated satisfactory performance and is suitable for its intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
K103278
OCT 2 8 2011
Image /page/0/Picture/1 description: The image shows a logo with the text "i-sens" in a stylized font. The "i" is enclosed in a circle, and there is a small dot above the "i". The text is in black and appears to be a company or brand logo. The logo is simple and modern.
465-6 Wolgye-dong, Nowon-gu, Seoul 139-845, Korea
Tel. 82-2-916-6191
510(k) Summary
(As required by 21 CFR 807.87)
| Introduction: | According to the requirements of 21 CFR.807.92, the following information
provides data needed to understand the basis for determining substantial
equivalence. | | | | |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-----------------------|------------------|--|
| 510(k) Number is: | K103278 | | | | |
| Type of 510(k): | Special 510(k) | | | | |
| Submitted By: | i-SENS, Inc.
465-6, Wolgye-dong, Nowon-gu, Seoul 139-845, Korea
Tel.) +82-2-916-6191
Fax) +82-2-942-2514
www.i-sens.com | | | | |
| Contact Person: | Dr. Hyun Joon Oh
Tel.) +82-33-903-0760
Fax) +82-33-748-6191 | | | | |
| Device Name: | Trade name:
ACURA PLUS Blood Glucose Monitoring System
Common Name:
Glucose Test System | | | | |
| Device | * ACURA PLUS Blood Glucose Meter and Test Strips | | | | |
| Classification: | Product Code | Classification | Regulation
Section | Panel | |
| | CGA - glucose oxidase,
glucose | Class II | 21 CFR
862.1345 | 75,
Chemistry | |
| | NBW - system, test, blood
glucose, over the counter | Class II | 21 CFR
862.1345 | 75,
Chemistry | |
1
* ACURA PLUS Control Solution
| Product Code | Classification | Regulation
Section | Panel |
|--------------------------------|----------------|-----------------------|------------------|
| JJX - Quality control material | Class I | 21 CFR
862.1660 | 75,
Chemistry |
Type of Test: Quantitative, Amperometric method Enzyme: Glucose oxidase (Aspergillus sp.)
- System Description: The ACURA PLUS Blood Glucose Monitoring System (BGMS) measures the glucose in whole blood sample by a small electrical current generated in the test strips and sent to the meter for measurement. The system consists of the following devices: ACURA PLUS Meter (Model GM505RA), ACURA PLUS Test Strips, ACURA PLUS Control Solutions for three different glucose concentration ranges (called "Low", "Normal" and "High" ranges, sold separately), Lancing Device, Lancets, User manual, Quick reference guide and Logbook.
- Intended Use: The ACURA PLUS Blood Glucose Meter is intended for use with the ACURA PLUS Blood Glucose Test Strips for the quantitative measurement of glucose in capillary whole blood from the fingertip and the alternate sites such as forearm, palm, thigh and calf. The alternate site testing should be used only during steady-state blood glucose conditions. The ACURA PLUS Control Solutions are for use with the ACURA PLUS Meter and ACURA PLUS Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
The ACURA PLUS Blood Glucose Monitoring System is intended for self testing outside the body by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program. The system is intended to be used by a single person and should not be shared. It is not intended for use on neonates and is not for the diagnosis of or screening for diabetes.
2
i-SENS, Inc. 465-6 Wolgye-dong, Nowon-gu, Seoul 139-845, Korea Tel. 82-2-916-6191
| Predicate Device: | |
|---|---|
| 1) Device name: | CareSens N Blood Glucose Monitoring System |
| 510(k) Number: | K083468 |
| 2) Device name: | ACURA Blood Glucose Monitoring System |
| 510(k) Number: | K083468/A001 |
Comparison with
Predicate Device:
The modified ACURA PLUS BGMS has the following similarities to the predicate devices:
-
same intended use,
-
same operating principle,
-
same fundamental scientific technology,
-
same product specifications,
-
same operating ranges,
-
manufactured by the same process.
The modifications from the predicate devices are as follows:
-
Meter outer casing design change,
-
Software modification of displaying averages stored in the meter's memory.
| Technological Characteristics: | The ACURA PLUS BGMS has the same fundamental scientific technology as the predicate devices (CareSens N BGMS, ACURA BGMS). |
|---|---|
| Assessment of Performance: | To verify whether the modified feature operates correctly, the validation study was conducted. The test results confirmed that the modified features operated properly. Thus, ACURA PLUS BGMS demonstrated satisfactory performance and is suitable for its intended use. |
| Conclusion: | The modifications of ACURA PLUS BGMS do not affect the safety and effectiveness of the device and the intended use. Therefore, based on the information provided in this submission, the ACURA PLUS BGMS is substantially equivalent to the predicate devices. |
.
3
Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized image of an eagle or bird-like figure, with three curved lines representing its wings or feathers.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993
ISENS Attn: Hyun Joon Oh 465-6 Wolgye-dong, Nowon-gu Seoul 139-845 Republic of Korea
OCT 2 8 2011
Re: k 103278
Trade/Device Name: ACURA PLUS Blood Glucose Monitoring System Regulation Number: 21 CFR §862.1345 Regulation Name: Glucose test system Regulatory Class: Class 11 Product Code: CGA, NBW, JJX Dated: October 13, 2011 Received: October 17, 2011
Dear Dr. Oh:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
4
Page 2 -
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Virro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please nate the regulation enlitled, "Misbranding by reference to premarket notification" (2) CFR Part 800 97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the responsible of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-204) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevicesforYou/ndustr/ddf 2017/12/2
Sincerely yours.
signature
Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
Indications for Use Form
510(k) Number (if known): K103278
Device Name: ACURA_PLUS Blood Glucose Monitoring System
Indications for Use:
The ACURA PLUS Blood Glucose Monitoring System consists of a measuring meter, test strips and control solutions. The ACURA PLUS Blood Glucose Meter is intended for use with the ACURA PLUS Blood Glucose Test Strips for the quantitative measurement of glucose in capillary whole blood from the fingertip and the alternate sites such as forearm, palm, thigh and calf. The alternate site testing should be used only during steady-state blood glucose conditions. The ACURA PLUS Control Solutions are for use with the ACURA PLUS Meter and ACURA PLUS Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
The ACURA PLUS Blood Glucose Monitoring System is intended for self testing outside the body by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program. The system is intended to be used by a single person and should not be shared. It is not intended for use on neonates and is not for the diagnosis of or screening for diabetes.
Prescription Use _____________________________________________________________________________________________________________________________________________________________ X (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
signature
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K103278
Page 1 of 1 _